Morning Market Gainers

shares gained 67.30 percent to $3.53 as the company announced that data demonstrating CMX157 to be 60-fold more potent versus hepatitis B virus than Gilead's Viread.

shares jumped 47.93 percent to $64.99 following announcement pivotal Phase 3 trial of SPK-RPE65 for genetic blinding conditions.

climbed 35.74 percent to $3.00 after the company reported that it has signed a 25-year exclusive hauling & recycling agreement for Shangqiu City.

shares gained 30.28 percent to $1.85 after the company agreed to sell its Professional Services segment to

for $130 million in cash.

shares rose 17.96 percent to $4.40 after the company reported a settlement in patent litigation for Absorica.

shares climbed 14.85 percent to $7.34 after dropping 53.53 percent on Friday. Chardan Capital upgraded Amicus Therapeutics from Neutral to Buy

shares surged 9.66 percent to $3.51. Morgan Stanley upgraded Keryx to Equal-weight.

shares rose 8.25 percent to $47.22 after the company reported that its board has authorized a $25 million stock repurchase program.

shares jumped 3.32 percent to $26.32 after Nelson Peltz's Trian Fund Management disclosed a $2.5 billion stake in GE.

shares gained 3.01 percent to $17.43 after the company reported that it has received the FDA approval for the SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System.